FR3117337B1 - Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable - Google Patents

Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable Download PDF

Info

Publication number
FR3117337B1
FR3117337B1 FR2012996A FR2012996A FR3117337B1 FR 3117337 B1 FR3117337 B1 FR 3117337B1 FR 2012996 A FR2012996 A FR 2012996A FR 2012996 A FR2012996 A FR 2012996A FR 3117337 B1 FR3117337 B1 FR 3117337B1
Authority
FR
France
Prior art keywords
cyclodextrin
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2012996A
Other languages
English (en)
Other versions
FR3117337A1 (fr
Inventor
Myriam Bouchfaa
Damien Rousseleau
Damien Lannoy
Pascal Odou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Lille
Original Assignee
Centre Hospitalier Universitaire de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Lille filed Critical Centre Hospitalier Universitaire de Lille
Priority to FR2012996A priority Critical patent/FR3117337B1/fr
Priority to EP21831313.8A priority patent/EP4259214A1/fr
Priority to CA3201193A priority patent/CA3201193A1/fr
Priority to US18/256,719 priority patent/US20240050588A1/en
Priority to PCT/EP2021/085133 priority patent/WO2022122992A1/fr
Priority to AU2021398541A priority patent/AU2021398541A1/en
Publication of FR3117337A1 publication Critical patent/FR3117337A1/fr
Application granted granted Critical
Publication of FR3117337B1 publication Critical patent/FR3117337B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique comportant du propofol et au moins une cyclodextrine et/ou un dérivé de cyclodextrine. De manière caractéristique, selon l’invention, elle comprend en outre, au moins un sel pharmaceuticalement acceptable, à l’exception des sels pharmaceuticalement acceptables basiques et/ou acides.
FR2012996A 2020-12-10 2020-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable Active FR3117337B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR2012996A FR3117337B1 (fr) 2020-12-10 2020-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
EP21831313.8A EP4259214A1 (fr) 2020-12-10 2021-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
CA3201193A CA3201193A1 (fr) 2020-12-10 2021-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un derive de cyclodextrine et un sel pharmaceuticalement acceptable
US18/256,719 US20240050588A1 (en) 2020-12-10 2021-12-10 Pharmaceutical composition containing propofol, a cyclodextrin or a cyclodextrin derivative and a pharmaceutically acceptable salt
PCT/EP2021/085133 WO2022122992A1 (fr) 2020-12-10 2021-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
AU2021398541A AU2021398541A1 (en) 2020-12-10 2021-12-10 Pharmaceutical composition containing propofol, a cyclodextrin or a cyclodextrin derivative and a pharmaceutically acceptable salt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2012996 2020-12-10
FR2012996A FR3117337B1 (fr) 2020-12-10 2020-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Publications (2)

Publication Number Publication Date
FR3117337A1 FR3117337A1 (fr) 2022-06-17
FR3117337B1 true FR3117337B1 (fr) 2023-04-28

Family

ID=74347396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2012996A Active FR3117337B1 (fr) 2020-12-10 2020-12-10 Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable

Country Status (6)

Country Link
US (1) US20240050588A1 (fr)
EP (1) EP4259214A1 (fr)
AU (1) AU2021398541A1 (fr)
CA (1) CA3201193A1 (fr)
FR (1) FR3117337B1 (fr)
WO (1) WO2022122992A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN187686B (fr) 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
ATE326985T1 (de) 2002-02-01 2006-06-15 Shimoda Biotech Pty Ltd Lyophilisierte pharmazeutische zusammensetzung von propofol
US9006216B2 (en) 2009-09-09 2015-04-14 Howard Martin Biocidal aldehyde composition for oil and gas extraction
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
CN107261152B (zh) * 2011-11-29 2022-03-04 优奥斯私人有限公司 包含环糊精和疏水性药物的可注射药物组合物的防腐方法
US10064954B2 (en) * 2015-06-23 2018-09-04 Nian Wu Polymer-cyclodextrin-lipid conjugates

Also Published As

Publication number Publication date
AU2021398541A9 (en) 2024-05-30
AU2021398541A1 (en) 2023-07-06
WO2022122992A1 (fr) 2022-06-16
CA3201193A1 (fr) 2022-06-16
EP4259214A1 (fr) 2023-10-18
US20240050588A1 (en) 2024-02-15
FR3117337A1 (fr) 2022-06-17

Similar Documents

Publication Publication Date Title
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
MA32556B1 (fr) Composition pharmaceutique
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
CY1112337T1 (el) Καινοφανης ενωση αλφα-(ν-σουλφοναμιδο) ακεταμιδιου ως αναστολεας της παραγωγης του βητα αμυλοειδους πεπτιδιου
WO2009046314A3 (fr) Analogues de la moénomycine, procédés de synthèse et utilisations de ceux-ci
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
BRPI0713446A2 (pt) inibidores prolila hidroxilase
MA31706B1 (fr) Formulations galéniques de composés organiques
NO20062483L (no) 5-(benz-(z)-yliden)-tiazolidin-4-onderivater som immunundertrykkende midler
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
ECSP088625A (es) Compuestos para el tratamiento de trastornos inflamatorios
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
BRPI0610125B8 (pt) composição farmacêutica, kit e utilização de uma composição
BR0206968A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como antagonistas receptores de quimiocina cxc
NO20092569L (no) Inhibitorer av Akt-aktivitet
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
BRPI0510305A (pt) composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
NO20080150L (no) Inhibitorer av AKT-aktivitet
CU23815A3 (es) Diarilureas para el tratamiento de hipertensión pulmonar
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
PA8846901A1 (es) Inhibidores de cinasa akt y p70 s6.
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220617

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4